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Available online 23 February 2016The human embryonic stem cell line RCe014-A (RC-10) was derived from a fresh oocyte voluntarily donated as
unsuitable and surplus to fertility requirements following ethics committee approved informed consent under
licence from the UK Human Fertilisation and Embryology Authority. The cell line shows normal pluripotency
marker expression and differentiation to the three germ layers in vitro. It has a mixed 46XY and 47XY +12
male karyotype and microsatellite PCR identity, HLA and blood group typing data is available.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Resource tableName of stem cell
constructRCe014-Alternative name RC-10, RC10
stitution Roslin Cells Ltd.
erson who created
resourceB.J. Tye, K. Bruce, P. Dand, G. Russell, D.M. Collins,
A. Greenshields, H. Bradburnontact person and
emailPaul.desousa@roslincells.com; Paul.desousa@ed.ac.uk
Janet.downie@roslincells.com
Aidan.courtney@roslincells.com
Malcolm.bateman@roslinfoundation.comate archived/stock date 29 March 2010 (seed bank)
pe of resource Biological reagent: cell line
b-type hESC, research grade
rigin Zygote (oocyte/1PN)
ey transcription factors Oct4 (conﬁrmed by ﬂow cytometry)
uthentication See Quality Control test summary, Table 1
nk to related literature
(direct URL links and
full references)N/Aformation in public
databaseshttp://hpscreg.eu/cell-line/RCe014-Athics Informed consent obtained. Scotland A Research
Ethics committee approval obtained (07/MRE00/56).
Conducted under the UK Human Fertilisation and
Embryology Authority licence no R0136 to centre 0202.Resource detailsiences & Regenerative Medicine
ance Crescent, Edinburgh, EH16
@roslincells.com (P.A. De
. This is an open access article underRCe014-A (RC-10) was received as a failed to fertilise oocyte/1PN
(pro-nuclear) embryo that was surplus to requirement or unsuitable
for clinical use. The embryo was grown to blastocyst stage and the cell
linewas derived bywhole embryo outgrowth onmitotically inactivated
human ﬁbroblast (HDF) feeder cells using xeno-free medium (XF
KODMEM) and expanded under xeno free and feeder free conditions.
By ﬂow cytometry, RCe014-A (RC-10) expressed the pluripotency
makers Oct-4, Tra-1-60 and SSEA-4 (93.4%, 94.1% and 98.9%, respective-
ly), whereas low expression of the differentiationmarker SSEA-1 (3.5%)
was observed (Fig. 1, Table 1). Differentiation to the three germ layers,
endoderm, ectoderm and mesoderm, was demonstrated using embry-
oid body formation and expression of the germ layer markers
α-fetoprotein, β-tubulin and muscle actin (Fig. 2).
A microsatellite PCR proﬁle has been obtained for the cell line, and
HLA Class I and II typing is available (Table 2). Blood group genotyping
gave the blood group AO1 (Table 2).
Veriﬁcation and authentication
The cell line was analysed for genome stability by G-banding (Fig. 3)
and showed a mixed 46XY and trisomy 12 (47XY +12) male genotype
in 12 and 3 cells analysed, respectively. The cell line is free from myco-
plasma contamination as determined by RC-qPCR. Microsatellite PCR
DNA proﬁling for cell identity is available (Table 2).
Materials and methods
Ethics
Derivation of hESC from surplus to requirement and failed to
fertilise/develop oocytes and embryos was approved by The Scotlandthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. RCe014-A (RC-10) was subjected to ﬂow cytometry analysis for markers of pluripotency with speciﬁc antibody (top row) or isotype control (bottom row) as indicated above the
histograms. Percentage staining is indicated in Table 1.
538 P.A. De Sousa et al. / Stem Cell Research 16 (2016) 537–540A Research Ethics Committee and local ethics board at participating
fertility clinics and conducted under licence no R0136 from the UK
HFEA with informed donor consent.Cell culture
Failed to activate oocytes and embryos were cultured in Sydney
cleavage medium (Cook Medical, Hertfordshire, UK) until day 3 and
Sydney blastocyst medium (Cook Medical) after day 3 of development.
Embryos were cultured at 36.5–37.5 °C, 5 ± 0.5% CO2, 5 ± 0.5% O2 in
drops under parafﬁn oil (Cook Medical) and transferred to fresh medi-
um at least every 2–3 days.
By day 8 of development, embryos were placed in derivation
conditions consisting of mitotically inactivated neonatal human dermal
ﬁbroblasts (HDFs) (Forticell Biosciences, NJ, USA) on tissue culture
plastic in XF KODMEM medium (Knockout-DMEM, 15% KOSR-XF,
2 mM L-glutamine, 1% MEM Non-essential amino acids, 2% XF Growth
Factor Cocktail, 0.1 mM β-mercaptoethanol, all ThermoFisher Scientiﬁc,
Paisley, UK) supplemented with 80 ng/ml human bFGF (ThermoFisher
Scientiﬁc).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% Pharma
grade FCS (GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM
L-glutamine (ThermoFisher Scientiﬁc). HDFs were mitotically
inactivated using gamma irradiation at 50GY using a Gammacell Elite
1000 machine. For use as a feeder layer, irradiated HDFs were platedTable 1
Summary of quality control testing and results for RC-10 (RCe014-A).
Classiﬁcation Test Purpose
Donor screening
HIV 1 + 2
Hepatitis B
Hepatitis C
Donor scree
Identity Microsatellite PCR (mPCR) DNA proﬁlin
Phenotype Flow cytometry Assess antig
commonly a
Genotype
(details provided in Table 2)
Blood group genotyping
(DNA analysis)
To establish
Karyology (G-banding) Conﬁrmation
HLA tissue typing To establish
Microbiology and virology
Mycoplasma Mycoplasma
Endotoxin Screening fo
Morphology Photography To capture a
Differentiation potential Embryoid body formation To show diffat 50,000 cells/cm2 in XF KODMEM medium supplemented with
80 ng/ml human bFGF (ThermoFisher Scientiﬁc). Cells were cultured
at 36.5–37.5 °C, 5 ± 0.5% CO2, 5 ± 0.5% O2 and 50%medium exchanged
6 days a week.
The established cell line was expanded and banked using CellStart
matrix and Stempro hESC Serum Free Medium (ThermoFisher
Scientiﬁc). Passaging was performed mechanically using an EZ passage
tool (ThermoFisher Scientiﬁc). hESC lines were expanded to 25–30
wells of a 6-well plate and cryopreserved in 0.5–1 ml Cryostor CS10
(Biolife Solution, Washington, USA).
Mycoplasma
Mycoplasma detection was performed using Applied Biosystems
PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and MicroSEQ™
Mycoplasma Real-Time PCR Detection Kit (ThermoFisher Scientiﬁc
(Applied Biosystems)) according to manufacturer's instruction.
Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according to
manufacturer's instructions. Brieﬂy, an unknown samplewas compared
with a standard curve of known levels of control endotoxin. An assay
was deemed valid if the coefﬁcient of correlation, r ≥ 0.980 and the CV
(%) for the standard curve was ≤10%.Result
ning for adventitious agents Negative
g to give cell line its signature, gender/species Performed
en levels & cell surface markers
ssociated with hESC
Oct 3/4: 93.4%
Tra 1-60: 94.1%
SSEA-4: 98.9%
SSEA-1: 3.5%
blood group of the line AO1
of normal ploidy by G-banding
46XY (12 cells)
47 XY + 12 (3 cells)
full HLA type I and II genotype of the line HLA typed class I and class II
testing by RT-qPCR Negative
r endotoxin levels 1.2 EU/ml
visual record of the line Normal
erentiation to three germ layers
Expression of muscle actin,
β-tubulin and α-feto protein
Fig. 2. In vitro differentiation of RCe014-A (RC-10) to ectoderm (β-tubulin III), mesoderm (muscle actin), and endoderm (α-fetoprotein). Speciﬁc staining shown in green, cell nuclei are
counterstained with DAPI (blue).
Table 2
Microsatellite PCR, blood group and HLA tissue typing results for RCe014-A (RC-10).
Microsatellite PCR results
D3S1358 1 D3S1358 2 vWA 1 vWA 2 D16S539 1 D16S539 2 D2S1338 1 D2S1338 2
16 18 16 18 9 9 19 26
Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2 D21S11 1 D21S11 2 D18S51 1 D18S51 2
X Y 15 15 27 28 13 13
D19S433 1 D19S433 2 THO1 1 THO1 2 FGA 1 FGA 2 CSF1PO 1 CSF1PO 2
14 15 7 9.3 24 25 10 10
D5S818 1 D5S818 2 D7S820 1 D7S820 2 D13S317 1 D13S317 2 TPOX 1 TPOX 2
Blood group genotyping
11 11 8 12 10 13 10 11
RhD RhC Rhc RhE Rhe Fy a Fy b Fy GATA
pos pos pos neg pos neg pos neg
Jka Jkb K k M N S S
pos pos neg pos pos neg pos pos
Kp a Kp b Do a Do b ABO
ND ND pos pos AO1
ND = not determined
HLA tissue typing
HLA class I type HLA-A*01, A*02; B*40, B*57; Cw*03, Cw*06
HLA class II type HLA-DRB1*01, DRB1*04; DRB4*01; DQB1*03, DQB1*05
Comment B*40 is expressed serologically as B60, Cw*03 is expressed serologically as Cw10, DQB1*03 is expressed serologically as DQ8
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Pluripotency was determined using the Human and Mouse
Pluripotent Stem Cell Analysis kit (BD, Oxford, UK). Oct 3/4 and SSEA-
4 were included as pluripotency markers, and SSEA-1 as a differentia-
tion marker. FITC conjugated Tra-1-60 (BD) was used as an additional
pluripotency marker. Fixed and permeabilised cells were analysedFig. 3. RCe014-A (RC-10) was analysed by Giesma staining and showedusing a FACS Aria ﬂow cytometer (BD). Percentage expression of each
marker was compared to isotype control or unstained cells.
Immunocytochemistry
hESCwasﬁxed inmethanol (ThermoFisher Scientiﬁc), blockedusing
10% goat serum (Sigma-Aldrich, Dorset, UK) in PBS (Lonza) containinga mixed 46XY (12 cells) and 47XY +12 (3 cells) male karyotype.
540 P.A. De Sousa et al. / Stem Cell Research 16 (2016) 537–5400.01% Tween-20 (Sigma) and stained with AFP (1:500; Sigma),
β-tubulin III (1:1000; Sigma), muscle-speciﬁc actin (1:50; DAKO,
Glostrup, Denmark), and secondary antibody anti-goat IgG-AlexaFluor
488 (1:200; ThermoFisher Scientiﬁc). Images were acquired using a
Zeiss S100 Axiovert ﬂuorescence microscope or Nikon eC1 confocal
microscope.
In vitro differentiation
Conﬂuent hESC cells lifted using a cell scraper (Corning) and embry-
oid bodies EBs generated in ultra low attachment plates (Corning) in
EB medium (20% FBS (GE Healthcare (PAA)), 80% KO-DMEM 1 mM
L-glutamine, 0.1 mM β-mercaptoethanol, 1% nonessential amino acids
(all ThermoFisher Scientiﬁc)). After 9 days in suspension culture, EBs
were being transferred onto glass slide tissue culture chambers
(Nunc, ThermoFisher Scientiﬁc) coated with 0.1% gelatin (Sigma) at
0.1 ml/cm2 and cultured for 14 days.
Genomic analysis
All outsourced assayswere carried out under a Quality and Technical
Agreement. DNA was extracted using the QIAamp DNA Mini kit
(Qiagen, Manchester, UK) according to manufacturer's recommenda-
tions and provided in recommended quantities to the service providers.Microsatellite PCR, or Short TandemRepeat analysis, was used to de-
termine cell line identity and was carried out by Public Health England.
A proﬁle was obtained for the following core alleles: vWA, D16S539,
Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.
Blood group genotypingwas carried out by theMolecular Diagnostics
laboratory at NHSBT.
Karyotype analysis was carried out by The Doctors Laboratory
(London, UK) or the Western General Cytogenetics Laboratory
(Edinburgh, UK). Live cells at 60–70% conﬂuency were shipped over-
night in warm containers, ﬁxed and analysed by standard G-banding
analysis. For research grade lines, 20 spreads were analysed.
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